Evidence map›Paper›PMID 41444774›Full record

ArticleScientific reports2025

HMBOX1 plays a critical role in plumbagin-induced growth inhibition of hepatocellular carcinoma cells.

Yanfei Wei, Tao Cheng, Hong Liu, Yuanzheng Ma, Huan Liu, Yuanqin Du, Shuye Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanfei Wei *Department of Physiology, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Tao Cheng *Department of Physiology, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Hong LiuDepartment of Physiology, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Yuanzheng MaDepartment of Physiology, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Huan LiuGuangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Yuanqin DuGuangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, 530200, China.
Shuye DengLaboratory of Medical Molecular Biology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, NO.89-9 Dong Ge Road, Nanning, 530023, China. dengsy@gxtcmu.edu.cn.

Funding

the Natural Science Foundation of Guangxi 2019GXNSFDA245003the Natural Science Foundation of Guangxi 2023GXNSFBA026081the Natural Science Foundation of Guangxi 2024JJA140721the Research Launching Fund Project from Guangxi University of Chinese Medicine Introduced the Doctoral 2020BS027the third batch of"Qihuang Project"high-level talent team cultivation project of Guangxi University of Traditional Chinese Medicine 202402
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the commonly lethal malignancies worldwide and represents a major global health-care challenge. We have previously demonstrated that plumbagin (PLB) could inhibit the development of tumor in liver, but the mechanism is still not fully clear. Here we identified a transcription repressor-homeobox containing 1 (HMBOX1) as a regulator in the development of HCC.Knockdown of HMBOX1 resulted into expansive of tumor cells, while overexpression led to growth inhibition. Mechanistically, PLB promoted HMBOX1 expression, leading to inactivation of PI3K/Akt-mTOR of liver cancer cells. Moreover, PLB also inhibited tumor formation in a xenograft transplantation model via PI3K/Akt/mTOR signaling. Collectively, our results suggested that HMBOX1 played a key role in PLB-induced inhibition of HCC growth through PI3K/Akt/mTOR signaling pathway.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, HepatocellularHomeodomain ProteinsLiver NeoplasmsNaphthoquinonesAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAntineoplastic Agents, PhytogenicHomeodomain ProteinsMTOR protein, humanNaphthoquinonesPhosphatidylinositol 3-KinasesplumbaginProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesHepatocellular carcinomaHMBOX1PI3K/Akt/mTOR pathwayPlumbagin

Identifiers

PMID41444774
PMCPMC12855803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.